Recombinant human anti-CD20 momoclonal antibody(Shanghai Crosslink Pharma)

重组抗CD20人源化单克隆抗体（上海上药交联医药）

Report date: 2024/03/18 16:59:00

Base Information

Drug NameRecombinant human anti-CD20 momoclonal antibody(Shanghai Crosslink Pharma)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsPemphigusMyasthenia Gravis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Crosslink Pharmaceutical R & D Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Crosslink Pharmaceutical R & D Co Ltd
Inactive CompaniesN/A
Active IndicationsPemphigusMyasthenia Gravis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A